HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Got Ideas For Reducing Industry's Regulatory Burden? FDA Wants To Know

This article was originally published in The Rose Sheet

Executive Summary

CFSAN and other FDA centers ask for "broad public comment" the agency will use "to guide our initial review of our regulations" required in President Trump's January executive order for federal agencies to "evaluate existing regulations and identify those that may merit repeal, replacement, or modification."

You may also be interested in...



US Regulatory SUNSET Misses FDA’s OTC Drug Regulations, But Reaches Supplement Rules

Expiration dates in HHS’ final SUNSET rule exclude OTC drugs after CCHPA and other groups argue the rule would create more problems than it would solve. But dietary supplement regulations are subject to the rule.

Cosmetics Reg Reform Ill-Situated As Trump, FDA Explore 'Burden Reduction'

Any movement to advance proposed cosmetics reform legislation could be seen as running counter to President Trump's executive orders earlier this year, which now have FDA centers seeking "broad public comment" on how to achieve "meaningful burden reduction."

Deals, Dates And Difficulties: Health And Wellness Industry News

Woodward keynotes CRN's Conference; GMPs on AHPA's reg comment radar; Unilever acquires Pukka Herbs; CVS brand consumer health products in vending machines; and more news in brief.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121182

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel